Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label rollover study of linsitinib
2013-004076-34Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of linsitinib in Nonhematologic neoplasms, adrenal cancer (ACC) and cancer (3 arms), sponsored by Astellas Pharma. Primary endpoint: Number of subjects with adverse events. Started Jan 2014; status: completed.
02
Drugs
linsitinib
03
Conditions
Nonhematologic neoplasmsadrenal cancer (ACC)cancer
Beyond the preview
Go deeper on 2013-004076-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004076-34.